Attached files

file filename
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-2.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - MABVAX THERAPEUTICS HOLDINGS, INC.ex32-1.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
10-K - ANNUAL REPORT - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10k_dec312017.htm
 
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
 
We consent to the incorporation by reference in the registration statements (No. 333-222204) on Form S-8, and (Nos. 333-221114, 333-221026, 333-219291, and 333-218473) on Form S-3 of MabVax Therapeutics Holdings, Inc., of our report dated April 2, 2018, related to our audit of the consolidated financial statements of MabVax Therapeutics Holdings, Inc., as of December 31, 2017 and 2016 and for the years then ended, which report included an explanatory paragraph relating to MabVax Therapeutics Holdings, Inc.’s ability to continue as a going concern, included in this 2017 Annual Report of MabVax Therapeutics Holdings, Inc. on Form 10-K.
 
/s/ CohnReznick LLP
 
San Diego, California
April 2, 2018